NASHVILLE, Tenn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced participation in investor conferences hosted by both H.C. Wainwright and Lake Street Capital Markets. Information for each can be found below:
Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 8 – 9, 2025
Location: In-person at the Lotte New York Palace Hotel and virtual 
Format: Company presentation on Monday, September 8 at 5:00 pm ET, and one-on-one meetings
Link to live and replay: Click here
Event: Lake Street Capital Markets 9th Annual Best Ideas Growth Conference (BIG9)
Date: September 11, 2025
Location:  In-person at the Yale Club of New York City
Format: One-on-one meetings 
Investors wishing to participate are encouraged to reach out to their H.C. Wainwright or Lake Street sales representatives.
About Insight Molecular Diagnostics, Inc.
Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.Insight Molecular Diagnostics.com/ for more information.
GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.
Investor Contact:
Doug Farrell 
LifeSci Advisors LLC 
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$2.73 | 
| Daily Volume: | 0 | 
| Market Cap: | US$45.970M | 
 October 06, 2025  September 24, 2025  September 08, 2025  September 08, 2025  August 11, 2025  | |

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load